Brandon May

In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in low-density lipoprotein cholesterol (LDL-C), as well as reductions in lipoprotein(a), apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), according to study results published in the Journal of Clinical Lipidology. In addition, efficacy and safety results were similar in patients…

Persistent high residual inflammatory risk is associated with an increased major adverse cardiac and cerebrovascular accident risk in patients undergoing percutaneous coronary intervention who have a low baseline low-density lipoprotein level.

Investigators substantiated strategies to encourage approval rates for proprotein convertase subtilisin/kexin type 9 inhibitors.

There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.

Researchers analyzed the genetic differences between homo- and heterozygous familial hypercholesterolemia in a pediatric population.